HISTORY
Discovery of the molecular code for redox-related signaling
1999
Initiation of molecular modeling
against BRD4 target molecule
2012

•MSA with Wuxi Apptec Contract
•Patent Filing
•Established Epigenetics Research Institute
(R&D Center)
•KWB-BR01, -02, -03, -04 P.O.C. Studies
•Preclinical Test
2019


2005
Identification of redox model including
Identification of anti-cancer & anti-inflammatory mechanism
2018
•Completed four BRD4 target molecular
modeling
•BenoBio Co., Ltd. established
•Collaboration with the Catholic University
of Korea Hospital
•Drug Delivery System
technology Contract with Germany
•Contract with the Catholic University of
Korea